INTRODUCTION
Personalized cancer medicine approaches, inhibiting kinases in tumors driven by defined genomic alterations, have demonstrated striking efficacy in many cancer types.
However, acquired resistance inevitably develops, limiting the benefit of targeted therapies (1) . Acquired resistance mechanisms are typically identified by biopsying a single resistant tumor lesion for molecular analysis. This information is sometimes used to guide subsequent therapy for individual patients. For example, recent trials evaluating therapeutic strategies designed to overcome resistance mechanisms actually require identification of a specific molecular alteration in a post-progression tissue biopsy as a condition for enrollment (NCT02192697, NCT02094261).
However, tumors can display high levels of molecular heterogeneity (2) (3) (4) (5) (6) (7) . Indeed, exposure to therapy may result in selection of sub-clonal cell populations, capable of growing under drug pressures (8) (9) (10) (11) . Therefore, a single-lesion biopsy at disease progression may vastly underrepresent the molecular heterogeneity of resistant tumor clones in an individual patient and may fail to detect the existence of distinct but important resistance mechanisms that could impact treatment responses.
The impact of tumor heterogeneity, arising as a result of acquired resistance, on response to subsequent lines of targeted therapy has been hypothesized, but never documented definitively. Here, we show that different metastatic biopsies from the same colorectal cancer (CRC) patient display genetically distinct mechanisms of resistance to EGFR blockade. By assessing multiple biopsies in parallel with circulating tumor DNA (ctDNA) analysis, we demonstrate that distinct resistance mechanisms emerging in different metastases in the same patient can drive lesion-specific responses to the next line of targeted therapy.
RESULTS

Emergence of a MEK1 K57T mutation upon acquired resistance to cetuximab
The patient's initial clinical course is summarized in Fig. 1A . Following adjuvant chemotherapy for stage IIIC colorectal adenocarcinoma, the patient was found to have a new liver metastasis and tumor recurrence at the site of surgical colonic anastomosis. A simultaneous low anterior resection and partial hepatectomy were performed, but she developed new liver metastases 2 months later.
Molecular analysis of the primary tumor revealed wild-type (WT) KRAS and NRAS genes. The anti-EGFR antibodies, cetuximab and panitumumab, improve survival in combination with chemotherapy in RAS WT CRC (12, 13) . The patient responded to palliative chemotherapy with irinotecan and cetuximab for 15 months. The clinical response was attributed to cetuximab, as the patient's disease progressed while receiving irinotecan-containing chemotherapy as the prior line of therapy. Ultimately, her liver metastases progressed, and a core needle biopsy of a progressing segment 8 liver metastasis was obtained. The patient's disease continued to progress despite subsequent treatment with FOLFOX and bevacizumab, followed by regorafenib.
Molecular analysis of the post-progression liver metastasis biopsy was performed to determine the mechanism of acquired resistance to cetuximab and to guide subsequent therapy.
The post-progression liver biopsy and the primary tumor were analyzed with a nextgeneration sequencing panel covering 1000 genes, ( Supplementary Table S1 ). A targeted sequencing panel ( Supplementary Table S2 ) was also performed on these specimens and on two additional tumor specimens obtained prior to treatment with irinotecan and cetuximab ( Fig. 1) . A truncating mutation in TP53 at codon 171 (p.E171*; c.511g>t) was identified in all tumor specimens, suggesting that this mutation arose early in the clonal development of this CRC ( Fig. 1 , Supplementary Table S3 ). A lysine-tothreonine substitution at codon 57 (p.K57T; c.170a>c) of MEK1 (encoded by the MAP2K1 gene) was identified in the post-progression liver lesion, but was not detected in all three tumor specimens obtained prior to cetuximab ( Fig. 1 , Supplementary Table   S3 ). Mutations in p.K57 in MEK1 were recently implicated in de novo resistance to anti-EGFR antibodies in CRC (14, 15) , they have not previously been observed in the setting of acquired resistance. No other alterations previously implicated in resistance to anti-EGFR antibodies (6, 8, 9, 16) were identified, although the presence of additional subclonal resistance alterations not detected in our analysis of this tumor biopsy cannot be ruled out. MEK1 signals downstream of EGFR, and mutations at p.K57 in MEK1 occur in lung adenocarcinoma and can activate MEK1 kinase activity (17, 18) . Thus, MEK1 mutation could bypass the effect of EGFR inhibition and likely represents a novel mechanism of acquired resistance to cetuximab in this patient.
Role of MEK1 mutation in acquired resistance to cetuximab
Modeling acquired resistance to targeted therapies in cancer cells has proven effective in predicting clinically-relevant resistance mechanisms and in guiding therapeutic strategies to overcome resistance (19, 20) . A cetuximab-sensitive RAS-WT CRC cell line (HCA46) was treated with cetuximab until resistant clones emerged. These resistant clones developed a lysine-to-asparagine substitution at codon 57 (p.K57N) of MEK1the same codon mutated in the patient's post-progression biopsy ( Fig. 2A , Supplementary  Fig. S1A ). These cells exhibited constitutive activation (phosphorylation) of MEK and ERK despite cetuximab treatment ( Supplementary Fig.   S1B ). Exogenous expression of either K57T (identified in the patient) or K57N (identified in the cell line) mutant MEK1, but not wild-type MEK1, in an independent RAS-WT CRC cell line, LIM1215, was sufficient to confer resistance to cetuximab or panitumumab ( Figure 2B , Supplementary Fig.S1C-D) . However, the combination of the MEK inhibitor trametinib with either cetuximab or panitumumab was able to restore sensitivity, confirming that EGFR-dependence is maintained in the setting of acquired resistance, and suggesting a potential therapeutic strategy to overcome resistance to EGFR blockade caused by this mutation (Fig. 2C , Supplementary Fig. S2A -E).
Subsequent targeted therapy and serial ctDNA monitoring
Accordingly, the patient was treated with the combination of panitumumab and trametinib, which have been administered together previously(21). The patient's serum carcinoembryonic antigen CEACAM5 (CEA) levels decreased by ~60% during therapy ( Fig. 3A) . A repeat computed tomography (CT) scan of the abdomen after 3 months of therapy demonstrated a reduction in the size of the patient's segment 8 liver metastasis, which harbored the MEK1 p.K57T mutation ( Fig. 3B ), but revealed that some other metastatic lesions had in the meantime progressed.
Peripheral blood for plasma ctDNA analysis was collected prior to initiation of panitumumab and trametinib and throughout treatment. Plasma collected prior to therapy was analyzed using a next-generation sequencing method, which we developed to interrogate 226 cancer-related genes in ctDNA (15) . As expected, this analysis detected the TP53 p.E171* and MAP2K1 p.K57T variants, but surprisingly unveiled a previously unrecognized KRAS p.Q61H (c.183a>c) mutation ( Supplementary Table S4 ).
Indeed the KRAS p.Q61H mutation was not observed in the segment 8 liver metastasis biopsy by NGS or by high-sensitivity digital droplet polymerase chain reaction (ddPCR) ( Fig. 3B , Supplementary Table S3 ), suggesting that this mutation was not present in this metastasis, but was already present in a separate metastatic lesion at the start of panitumumab and trametinib therapy.
Changes in the relative abundance of specific mutations in ctDNA during panitumumab and trametinib treatment were monitored by ddPCR. Levels of the TP53 p.E171* variant dropped after initiation of therapy, but rose later during treatment in concert with the patient's CEA levels ( Fig. 3A , Supplementary Table S5 ). Since TP53 p.E171* was detected in all tumor specimens from this patient, it likely represents an early clonal or "founder" mutation present in all tumor cells, and thus a marker of overall disease burden. Another "founder" mutation, IGF1R p.R366W (c.1096c>t), showed a similar pattern (Supplementary Figure S3A -B, Supplementary Tables S5-S6 ).
However, levels of MAP2K1 p.K57T declined sharply and remained low throughout treatment, indicating effective suppression of MEK1 mutant clones by panitumumab and trametinib. Suppression persisted even as the patient's CEA and TP53 p.E171* levels began to rise, suggesting that a different molecular alteration must be driving disease progression ( Fig. 3A , Supplementary Table S6 ). Conversely, KRAS p.Q61H rose markedly during therapy, indicating outgrowth of a resistant KRAS-mutant clone. Biopsy of a different segment 5 liver metastasis that progressed despite panitumumab and trametinib revealed that this lesion harbored the same KRAS p.Q61H mutation identified in ctDNA, along with the TP53 p.E171* mutation, but the MAP2K1 p.K57T mutation was not detected by sequencing or ddPCR ( Fig. 3B -C, Supplementary Table S3 ). Notably, the KRAS or MAP2K1 mutations could not be detected by high-sensitivity ddPCR in any of the tumor specimens obtained prior to the prolonged response to cetuximab ( Supplementary Table S3 ), but preexistence of rare clones harboring these mutations below the limit of detection cannot be excluded.
After 4 months of panitumumab and trametinib, the patient discontinued therapy as CEA levels continued to rise. Analysis of ctDNA obtained one week later revealed a rebound in MAP2K1 p.K57T levels ( Fig. 3A ).
DISCUSSION
The inevitable emergence of acquired resistance is a major limitation to the efficacy of targeted therapies in oncology. Identification of actionable resistance mechanisms may offer patients the opportunity to benefit from therapies designed to overcome resistance.
Here, we describe how distinct acquired resistance mechanisms can arise concomitantly in separate metastases within the same patient, leading to mixed responses to subsequent targeted therapies. This demonstrates how molecular analysis of a singlelesion biopsy, currently the diagnostic standard for targeted therapy trials, can regularly fail to detect clinically-relevant molecular alterations, which can be responsible for lesionspecific or even sub-clone-specific clinical response and consequent treatment failure.
In this CRC patient, we identified a MEK1 p.K57T mutation in a biopsy of a single progressing liver metastasis, following prolonged response to cetuximab. Based on preclinical modeling and characterization of this novel resistance mechanism, the patient was treated with the combination of panitumumab and trametinib. Imaging revealed that the lesion harboring the MEK1 mutation responded. However, a neighboring metastasis progressed and was found to harbor a completely distinct resistance mechanism (KRAS p.Q61H), confirming that separate metastases can independently evolve different resistance mechanisms, resulting in striking differences in lesion-specific response to targeted therapy.
Our original single-lesion biopsy was not sufficient to capture the molecular heterogeneity of this patient's cancer and failed to detect the simultaneous presence of an additional resistance mechanism (KRAS mutation) that eventually led to treatment failure. This underscores the potential pitfalls of selecting a targeted therapy strategy based on the molecular profile of a single resistant lesion. However, both mutations were readily detectable in ctDNA from blood collected prior to combinatorial therapy.
These findings also illustrate the potential of "liquid biopsies". Not only did real-time ctDNA analysis enable identification of a second resistance mechanism not captured by the single-lesion biopsy, but it did so while the patient still appeared to be responding to therapy, thereby predicting both the timing and cause of impending treatment failure.
ctDNA analysis also allowed monitoring of dynamic shifts in the clonal composition of the patient's tumor cells, demonstrating effective on-target suppression of the MEK1 mutant population by panitumumab and trametinib, contrasted with marked expansion of the KRAS mutant population driving disease progression.
In summary, while it has been proposed that tumor heterogeneity developing in the context of acquired resistance may have the potential to impact response to subsequent therapies, this has yet to be clearly documented. Here, we demonstrate how individual metastatic lesions can develop distinct resistance mechanisms to targeted agents, resulting in lesion-specific differences in response to the next line of targeted therapy.
As more trials evaluating targeted therapy strategies designed to overcome specific acquired resistance mechanisms enter the clinic, genomic results from single-tumor biopsies should be interpreted with caution. By contrast, liquid biopsy approaches have the potential to detect the presence of simultaneous resistance mechanisms residing in separate metastases in a single patient and to monitor the effects of subsequent targeted therapies. Therefore, ctDNA profiles, serial tumor biopsies and lesion-specific radiographic responses can be integrated to define mechanisms of drug resistance and to guide selection of therapeutic strategies in oncology.
METHODS
Patient care and specimen collection
All biopsies, tumor specimens, and peripheral blood draws for plasma isolation were 
Plasma Sample Collection
At least 10 mL of whole blood were collected by blood draw using EDTA as anticoagulant. Plasma was separated within 5 hours through 2 different centrifugation steps (the first at room temperature for 10 minutes at 1,600 × g and the second at 3,000 × g for the same time and temperature), obtaining up to 3 mL of plasma. Plasma was stored at -80°C until ctDNA extraction.
ctDNA isolation, genome equivalents quantification (GE/ml plasma), and analysis ctDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit DNA at known concentrations was also used to build the standard c u r v e . P r i m e r sequences are available upon request. Analysis of ctDNA by NGS and ddPCR was performed as previously described (15) . Detailed methods are provided in the Supplementary Methods.
Cell culture and generation of resistant cells
HCA46 cells were cultured in DMEM medium (Invitrogen), supplemented with 10% FBS, 2mM L-glutamine, antibiotics (100U/mL penicillin and 100 mg/mL streptomycin) and grown in a 37°C and 5% CO2 air incubator. LIM1215 were cultured in RPMI medium (Invitrogen), supplemented with 1µg/ml insulin.
HCA46 cetuximab-resistant derivatives were obtained by exposing cells to a chronic dose of 100µg/ml of cetuximab until resistant derivatives emerged.
Mutational analysis in cell lines
Genomic DNA samples were extracted by Wizard® SV Genomic DNA Purification System (Promega). For Sanger Sequencing, all samples were subjected to automated sequencing by ABI PRISM 3730 (Applied Biosystems). Primer sequences for MAP2K1
(exon2) are listed elsewhere (17, 19) .
Ectopic expression of MEK1 in CRC cells.
LIM1215 RAS wild-type cetuximab-sensitive cells were cultured in RPMI medium (Invitrogen) supplemented with 10% FBS, 1µg/ml insulin, 2mM L-glutamine, antibiotics (100U/mL penicillin and 100 mg/mL streptomycin) and grown in a 37°C and 5% CO2 air incubator. LIM1215 were transduced with lentiviral vector encoding MEK1 WT, MEK1 K57N or MEK1 K57T cDNA. MEK overexpression was verified by western blot analysis.
Drug proliferation assay
CRC cell lines were seeded at different densities ( 
Supplementary Methods
Supplementary Figures
• Supplementary Figure S1 : MEK1 K57 mutation confers resistance to anti-EGFR antibodies in CRC preclinical models.
• Supplementary Figure S2 : Dual blockade of EGFR and MEK restores sensitivity to CRC cells expressing MEK1 K57N or K57T.
• Supplementary Figure S3 : Longitudinal analysis of founder mutations in patient plasma during panitumumab and trametinib treatment.
Supplementary Tables
• Supplementary Table S1 : 1000 gene sequencing panel.
• Supplementary Table S2 : 40 gene targeted sequencing panel.
• Supplementary Table S3 : Summary of targeted sequencing and ddPCR data on tissue specimens.
• Supplementary Table S4 : Next generation sequencing data from plasma ctDNA.
• Supplementary Table S5 : Summary of serial ctDNA analyses.
• Supplementary Table S6 : Ratio of resistance-associated genetic alterations and founder mutations in serial plasma ctDNA timepoints. 
Supplementary Methods
Next Generation Sequencing analysis
Bioinformatic analysis
Sequence files were mapped to the hg19 reference genome using BWA-mem algorithm(1); PCR duplicates were then removed and the resulting BAM file(2) was used as input for several pipelines. All analyzes are comparison between a normal and tumor sample. We used a custom script in order to call somatic variations and gene copynumber alterations; Pindel(3) software was instead run in searching for INDEL events.
Each result was further annotated by main biological information and COSMIC database occurrence.
Bliss interaction index analysis
Bliss interaction index -defined as the difference between the Observed combined AAK1  BLK  CDK15  CSNK2A 2  EPHB3  FUS  IKZ F1  LMTK2  MDS2  NF1  PEA K1  PRKA CG  RPS6KA 2  SRPK3  TIE1  WHSC1L1   AATK  BLM  CDK16  CTNNB1  EPHB4  FY N  IL2  LMTK3  MECOM  NF2  PER1  PRKA R1 A  RPS6KA 3  SRSF3  TIMP3  WHSC2   ABI1  BMI1  CDK17  CUBN  EPHB6  GA B1  IL21R  LPP  MEF2B  NFE2L2  PGF  PRKCA  RPS6KA 4  SS18  TLK1  WIF1   ABL1  BMP2K  CDK18  CXCL1  EPS1 5  GA BRA 6  IL6ST  LRP1B  MELK  NFIB  PHF6  PRKCB  RPS6KA 5  SS18L1  TLK2  WNK1   ABL2  BMPR1A  CDK19  CXCR7  ERBB2  GA K  IL7R  LRRK1  MEN1  NFKB1  PHKG1  PRKCD  RPS6KA 6  SSX1  TLX1  WNK2   ACSL3  BMPR1B  CDK2  CY LD  ERBB3  GA S7  ILK  LRRK2  MERTK  NFKB2  PHKG2  PRKCE  RPS6KB1  SSX2  TLX3  WNK3   ACSL6  BMPR2  CDK20  DA PK1  ERBB4  GA TA 1  INPP4A  LTK  MET  NFKBIA  PHOX2 B  PRKCG  RPS6KB2  SSX4  TMPRSS2  WNK4   ACTR2  BMX  CDK3  DA PK2  ERC1  GA TA 2  INSR  LYL1  MINK1  NFKBIE  PI4 K2 A  PRKCH  RPS6KC1  STIL  TNFA IP3 Supplementary Table S4 . Next generation sequencing data from plasma ctDNA.
Supplementary Tables
The table shows the mutations found in the patient's plasma ctDNA (before initiation of panitumumab and trametinib) compared to genomic DNA isolated from peripheral blood mononuclear cells (PBMC) using the IRCC-TARGET next generation sequencing panel.
To uncover somatic mutations, we compared germline (PBMC) and ctDNA samples, and identified basepair mismatches (Fisher's Test) with fractional abundance above 1%. 
Mutations
